EKI Energy Services Regulatory Approval

EKI Energy Services Board Meeting Date

EKI Energy Services Limited has intimated a board meeting on 14 November 2026 to consider unaudited standalone and consolidated half-yearly results for the period ended September 2026. The trading window closes from 1 October to 16 November 2026.

EKI Energy Services Legal & Regulatory

EKI Energy's counterparty Vitol terminated an emission reduction agreement and invoked a USD 10 million bank guarantee. The company disputes the default claim and plans arbitration.

Value

₹94.00 Cr

EKI Energy Services Legal & Regulatory

SEBI penalised EKI Energy Services Rs 12 lakh and barred it from markets for two months. The company plans to appeal to the Securities Appellate Tribunal.

Value

₹0.12 Cr

EKI Energy Services Capacity Expansion

EKI Energy Services' shareholders approved altering the Memorandum of Association to add new business objects, including metal trading, renewable energy, and manpower services.

EKI Energy Services Annual General Meeting

EKI Energy Services Ltd announced the voting results for its recent postal ballot. Shareholders approved the special resolution to alter the company's memorandum of association.

EKI Energy Services Other Announcement

Quarterly shareholding pattern disclosure submitted by the company in compliance with SEBI Regulation 31.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.